CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >

2023 , Vol. 41 >Issue 4: 486 - 491

DOI: https://doi.org/10.12140/j.issn.1000-7423.2023.04.015

REVIEWS

Research progress of antimalarial drugs

  • WEI Luanting ,
  • LI Runze ,
  • GUAN Liangchao ,
  • ZHANG Qianyu ,
  • LI Cheng ,
  • CAO Yaming ,
  • ZHAO Yan
Expand
  • 1 Queen's University Belfast Joint College, China Medical University, Shenyang 110122, Liaoning, China
    2 The Second Clinical Department, China Medical University, Shenyang 110122, Liaoning, China
    3 The First Clinical Department, China Medical University, Shenyang 110122, Liaoning, China
    4 Department of Immunology, China Medical University, Shenyang 110122, Liaoning, China

Received date: 2023-04-24

  Revised date: 2023-06-17

  Online published: 2023-09-06

Supported by

National Natural Science Foundation of China(82002163)

Fold

Abstract

Antimalarial drug resistance presents the biggest challenge for treatment against malaria. Plasmodium parasites have developed different degrees of resistance to common traditional antimalarial drugs including artemisinin. Therefore, the improvement of traditional drugs and the research and development of new drugs are urgently needed. This paper discusses the malaria control strategies based on a systematic review of the resistance mechanisms against traditional antimalarial drugs, the improvement strategies and optimisation achievements based on traditional drugs, and the research advances of new antimalarial drugs.

Key words： Anti-malarial drugs; Drug resistance analysis; New drug development; Targeted drug; prevention strategy

Cite this article

WEI Luanting , LI Runze , GUAN Liangchao , ZHANG Qianyu , LI Cheng , CAO Yaming , ZHAO Yan . Research progress of antimalarial drugs[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023 , 41(4) : 486 -491 . DOI: 10.12140/j.issn.1000-7423.2023.04.015

References

[1] World Health Organization. World Malaria Report 2021[R]. Geneva: WHO, 2022.
[2] Arya A, KojomFoko LP, Chaudhry S, et al. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: a systematic review of clinical studies from two malaria endemic regions-India and sub-Saharan Africa[J]. Int J Parasitol Drugs Drug Resist, 2021, 15: 43-56.
[3] Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria[J]. Cochrane Database Syst Rev, 2018, 11(11): CD000363.
[4] Laurens MB. The promise of a malaria vaccine: are we closer?[J]. Annu Rev Microbiol, 2018, 72: 273-292.
[5] Mendis K, Rietveld A, Warsame M, et al. From malaria control to eradication: the WHO perspective[J]. Trop Med Int Health, 2009, 14(7): 802-809.
[6] Brashear AM, Cui LW. Population genomics in neglected malaria parasites[J]. Front Microbiol, 2022, 13: 984394.
[7] Zamil MF, ArefeenSazed S, HaqueHossainey MR, et al. Anti-malarial investigation of Acoruscalamus, Dichapetalumgelonioides, and Leucasaspera on Plasmodium falciparum strains[J]. J Infect Dev Ctries, 2022, 16(11): 1768-1772.
[8] Amelo W, Makonnen E. Efforts made to eliminate drug-resistant malaria and its challenges[J]. Biomed Res Int, 2021, 2021: 5539544.
[9] Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency[J]. Am J Health Syst Pharm, 2018, 75(3): 97-104.
[10] Dinis DV, Schapira A. Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique[J]. Bull Soc Pathol Exot, 1990, 83(4): 521-528.
[11] Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future[J]. Ann N Y Acad Sci, 2015, 1342: 62-67.
[12] Fukuda N, Tachibana SI, Ikeda M, et al. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda[J]. Parasitol Int, 2021, 81: 102277.
[13] Okombo J, Ohuma E, Picot S, et al. Update on genetic markers of quinine resistance in Plasmodium falciparum[J]. MolBiochem Parasitol, 2011, 177(2): 77-82.
[14] White NJ. The treatment of malaria[J]. N Engl J Med, 1996, 335(11): 800-806.
[15] Wellems TE, Plowe CV. Chloroquine-resistant malaria[J]. J Infect Dis, 2001, 184(6): 770-776.
[16] Mvango S, Matshe WMR, Balogun AO, et al. Nanomedicines for malaria chemotherapy: encapsulation vs. polymer therapeutics[J]. Pharm Res, 2018, 35(12): 237.
[17] Yang B, Sun YF, Lei Y, et al. Research progress on the treatment of malaria with artemisinin and its derivatives[J]. Chin J Parasitol Parasit Dis, 2021, 39(3): 393-402. (in Chinese)
  (杨博, 孙毅凡, 雷瑶, 等. 青蒿素及其衍生物治疗疟疾的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 393-402.)
[18] Ashley EA, Phyo AP. Drugs in development for malaria[J]. Drugs, 2018, 78(9): 861-879.
[19] Abuaku B, Boateng P, Peprah NY, et al. Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana[J]. Front Cell Infect Microbiol, 2022, 12: 1058660.
[20] Li N, Huang YM, Cai WB, et al. Advances in the study of the sensitivity of Plasmodium falciparum todihydroartemisinin-piperaquine[J]. J Pathog Biol, 2017, 12(10): 1025-1027. (in Chinese)
  (李娜, 黄亚铭, 蔡文斌, 等. 恶性疟原虫对双氢青蒿素-哌喹敏感性研究进展[J]. 中国病原生物学杂志, 2017, 12(10): 1025-1027.)
[21] Zhao H, Xiang Z, Zhou LC, et al. Research progress of amodiaquine as an antimalarial drug[J]. Chin J Parasitol Parasit Dis, 2022, 40(6): 786-791. (in Chinese)
  (赵卉, 向征, 周隆参, 等. 阿莫地喹作为抗疟药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(6): 786-791.)
[22] Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, et al. Artemisinin resistance and malaria elimination: where are we now?[J]. Front Pharmacol, 2022, 13: 876282.
[23] Urbán P, Fernàndez-Busquets X. Nanomedicine against malaria[J]. Curr Med Chem, 2014, 21(5): 605-629.
[24] Gujjari L, Kalani H, Pindiprolu SK, et al. Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria[J]. Parasite Epidemiol Control, 2022, 17: e00244.
[25] Guasch-Girbau A, Fernàndez-Busquets X. Review of the current landscape of the potential of nanotechnology for future malaria diagnosis, treatment, and vaccination strategies[J]. Pharmaceutics, 2021, 13(12): 2189.
[26] Joshi MC, Egan TJ. Quinoline containing side-chain antimalarial analogs: recent advances and therapeutic application[J]. Curr Top Med Chem, 2020, 20(8): 617-697.
[27] Faidallah HM, Panda SS, Serrano JC, et al. Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates[J]. Bioorg Med Chem, 2016, 24(16): 3527-3539.
[28] Kalita J, Chetia D, Rudrapal M. Design, synthesis, antimalarial activity and docking study of 7-chloro-4- (2-(substituted benzylidene)hydrazineyl)quinolines[J]. Med Chem, 2020, 16(7): 928-937.
[29] Guo ZR. Transformation of old drugs: a radical antimalarial drug tafenocil[J]. Acta Pharm Sin, 2022, 57(11): 3446-3450. (in Chinese)
  (郭宗儒. 老药改造: 根治性的抗疟药他非诺奎[J]. 药学学报, 2022, 57(11): 3446-3450.)
[30] Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria[J]. N Engl J Med, 2019, 380(3): 229-241.
[31] Zhan YL, Wu YS, Xu FF, et al. A novel dihydroxylated derivative of artemisinin from microbial transformation[J]. Fitoterapia, 2017, 120: 93-97.
[32] Tafenoquine, LiverTox: clinical and research information on drug-induced liver injury[R]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
[33] Summers RL, Pasaje CFA, Pisco JP, et al. Chemogenomics identifies acetyl-coenzyme a synthetase as a target for malaria treatment and prevention[J]. Cell Chem Biol, 2022, 29(2): 191-201.e8.
[34] Knecht W, Loffler M. Inhibition and localization of human and rat dihydroorotate dehydrogenase[J]. Adv Exp Med Biol, 2000, 486: 267-270.
[35] Hartuti ED, Sakura T, Tagod MSO, et al. Identification of 3, 4-dihydro-2H, 6H-pyrimido[1, 2-c][1, 3]benzothiazin-6-imine derivatives as novel selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase[J]. Int J Mol Sci, 2021, 22(13): 7236.
[36] Cheng X, Song ZH, Wang X, et al. A network pharmacology study on the molecular mechanism of protocatechualdehyde in the treatment of diabetic cataract[J]. Drug Des Devel Ther, 2021, 15: 4011-4023.
[37] Li RX, Ling DZ, Tang TK, et al. Discovery of novel Plasmodium falciparum HDAC1 inhibitors with dual-stage antimalarial potency and improved safety based on the clinical anticancer drug candidate quisinostat[J]. J Med Chem, 2021, 64(4): 2254-2271.
[38] Surur AS, Huluka SA, Mitku ML, et al. Indole: the after next scaffold of antiplasmodial agents?[J]. Drug Des Devel Ther, 2020, 14: 4855-4867.
[39] Dangi P, Jain R, Mamidala R, et al. Natural product inspired novel indole based chiral scaffold kills human malaria parasites via ionic imbalance mediated cell death[J]. Sci Rep, 2019, 9(1): 17785.
[40] Chavchich M, van Breda K, Rowcliffe K, et al. The spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasites[J]. Antimicrob Agents Chemother, 2016, 60(9): 5167-5174.
[41] Marin GE, Neag MA, Burlacu CC, et al. The protective effects of nutraceutical components in methotrexate: induced toxicity models-an overview[J]. Microorganisms, 2022, 10(10): 2053.
[42] White NJ, Pukrittayakamee S, Hien TT, et al. Malaria[J]. Lancet, 2014, 383(9918): 723-735.
[43] Chughlay MF, El Gaaloul M, Donini C, et al. Chemoprotective antimalarial activity of P218 against Plasmodium falciparum: a randomized, placebo-controlled volunteer infection study[J]. Am J Trop Med Hyg, 2021, 104(4): 1348-1358.
[44] Mayinger P. Phosphoinositides and vesicular membrane traffic[J]. Biochim Biophys Acta, 2012, 1821(8): 1104-1113.
[45] McNamara CW, Lee MC, Lim CS, et al. Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria[J]. Nature, 2013, 504(7479): 248-253.
[46] Paquet T, Le MC, Cabrera DG, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase[J]. Sci Transl Med, 2017, 9(387).
[47] Kundu M, Dutta A, Roy KK, et al. Identification of 5-(3-(methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)-3H-imidazo[4, 5-b]pyridine as novel orally bioavailable and metabolically stable antimalarial compound for further exploration[J]. Chem Biol Drug Des, 2023, 101(3): 690-695.
[48] Ursing J, Schmidt BA, Lebbad M, et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage?[J]. Infect Genet Evol, 2007, 7(5): 555-561.
[49] Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria[J]. N Engl J Med, 2014, 371(5): 411-423.
[50] D'Alessandro U. Progress in the development of piperaquine combinations for the treatment of malaria[J]. Curr Opin Infect Dis, 2009, 22(6): 588-592.
[51] Kay K, Hodel EM, Hastings IM. Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness[J]. Antimicrob Agents Chemother, 2015, 59(10): 6419-6427.
[52] Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria[J]. Malar J, 2011, 10: 144.
[53] Tan KR, Magill AJ, Parise ME, et al. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis[J]. Am J Trop Med Hyg, 2011, 84(4): 517-531.
[54] Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity[J]. Int J Parasitol, 2002, 32(13): 1655-1660.
[55] Tanneru N, Nivya MA, Adhikari N, et al. Plasmodium DDI1 is a potential therapeutic target and important chromatin-associated protein[J]. Int J Parasitol, 2023, 53(3): 157-175.
[56] WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for malaria[R]. Geneva: WHO, 2022.
[57] Attaher O, Zaidi I, Kwan JL, et al. Effect of seasonal malaria chemoprevention on immune markers of exhaustion and regulation[J]. J Infect Dis, 2020, 221(1): 138-145.
[58] Aregawi M, Smith SJ, Sillah-Kanu M, et al. Impact of the mass drug administration for malaria in response to the ebola outbreak in Sierra Leone[J]. Malar J, 2016, 15: 480.
[59] Nikiema S, Soulama I, Sombié S, et al. Seasonal malaria chemoprevention implementation: effect on malaria incidence and immunity in a context of expansion of P. falciparum resistant genotypes with potential reduction of the effectiveness in sub-saharan Africa[J]. Infect Drug Resist, 2022, 15: 4517-4527.
[60] Ni SJ. The COVID-19 epidemic increases the global burden of malaria[N]. Acta Scientiae Sinica, 2021-12-10( 003). (in Chinese)
  (倪思洁. 新冠肺炎疫情加重全球疟疾负担[N]. 中国科学报, 2021-12-10 (003).)
[61] Lopes EA, Santos MMM, Mori M. Antimalarial drugs: what's new in the patents?[J]. Expert Opin Ther Pat, 2023, 33(3): 151-168.
[62] Ambroise-Thomas P. The tragedy caused by fake antimalarial drugs[J]. Mediterr J Hematol Infect Dis, 2012, 4(1): e2012027.
[63] Phyo AP, Von Seidlein L. Challenges to replace ACT as first-line drug[J]. Malar J, 2017, 16(1): 296.
Options
Outlines

/

〈 〉